

# Europäisches Patentamt European Patent Office Office européen des brevets



11 Publication number:

0 475 386 A2

12

# **EUROPEAN PATENT APPLICATION**

21 Application number: 91115381.5

2 Date of filing: 11.09.91

(a) Int. Cl.5: **C07C** 69/593, C07C 67/347, C07C 45/72, C07C 231/12, C07F 15/00

(3) Priority: 11.09.90 US 580919

Date of publication of application: 18.03.92 Bulletin 92/12

Designated Contracting States:
 BE DE ES FR GB IT NL

7) Applicant: THE UNIVERSITY OF NORTH
CAROLINA AT CHAPEL HILL
Office of Research Services, CB 4100, 300
Bynum Hall
Chapel Hill, NC 27599-4100(US)

Inventor: Brookhart, Maurice S. Route 7, Box 648-B Chapel Hill, North Carolina 27514(US) Inventor: Sabo-Etienne Sylviane 13, rue Flora Tristan F-31320 Castanet Tolosan(FR)

Representative: Abitz, Walter, Dr.-Ing. et al Abitz, Morf, Gritschneder, Freiherr von Wittgenstein Postfach 86 01 09 W-8000 München 86(DE)

(S) Rhodium-catalyzed olefin dimerization.

(57) A process is disclosed for preparing functionalized linear olefins by dimerizing terminal olefins in the presence of a cationic rhodium compound. Novel rhodium compounds useful in this process are also disclosed.

EP 0 475 386 A2

#### FIELD OF THE INVENTION

10

25

30

35

X-

This invention relates to a process for the rhodium-catalyzed linear dimerization of terminal olefins.

# 5 BACKGROUND OF THE INVENTION

The dimerization and codimerization of  $\alpha$ -olefinic compounds in the presence of a group VIII noble metal salt is disclosed by Alderson (U.S. 3,013,066). The dimerization and codimerization of alkenes and alkyl acrylates in the presence of rhodium trichloride is disclosed by Alderson et al. (J. Amer. Chem Soc. 1965, 87, 5638-5645)

Nugent et al. (J. Molecular Catalysis 1985, 29, 65-76) disclose a process for the linear dimerization of alkyl acrylates using chlorobis(ethylene)rhodium(l) dimer in combination with a Lewis acid promoter and a proton source.

Singleton (U.S. 4,638,084) discloses a process for dimerizing a lower alkyl acrylate or a lower alkyl methacrylate to the corresponding dialkyl hexenedioates and dialkyl 2,5-dimethylhexenedioates by contact with a catalyst prepared by reacting chlorobis(ethylene)rhodium(I) dimer and silver tetrafluoroborate.

Brookhart et al. (J. Amer. Chem. Soc. 1988, 110, 8719-8720) disclose the use of a cationic rhodium catalyst containing a pentamethylcyclopentadienyl ligand in the dimerization of ethylene to butenes.

### SUMMARY OF THE INVENTION

This invention provides a process for preparing functionalized linear olefins which comprises reacting a first olefin,  $H_2C = CR^1R^2$ , with a second olefin,  $H_2C = CR^3R^4$ , in the presence of a cationic rhodium compound,  $[L^1RhL^2L^3R]^{\frac{1}{2}}X^-$ ; wherein

compound, [L¹RhL²L³R] X<sup>-</sup>; wherein

R¹ is selected from the group consisting of H and C₁-C₁₀ alkyl;

R² is selected from the group consisting of H, C₁-C₁₀ alkyl, phenyl, C₂-C₁₂ alkyl
substituted phenyl, -COOR⁵, -C(O)NR⁶R⁷, and -C(O)H;

is selected from the group consisting of H and C₁-C₁₀ alkyl;

R<sup>4</sup> is selected from the group consisting of -COOR<sup>8</sup>, -C(0)NR<sup>9</sup>R<sup>10</sup>, and -C(0)H; R<sup>5</sup> and R<sup>8</sup> are independently selected from the group consisting of C<sub>1</sub>-C<sub>10</sub> alkyl;

R<sup>6</sup>, R<sup>7</sup>, R<sup>9</sup>, and R<sup>10</sup> are independently selected from the group consisting of H and C<sub>1</sub>-C<sub>10</sub> alkyl;


L<sup>2</sup> and L<sup>3</sup> is an anionic pentahapto ligand; are neutral 2-electron donor ligands;

 $L^2$  and  $L^3$  are neutral 2-electron donor ligands; R is selected from the group of H,  $C_1$ - $C_{10}$  alkyl,  $C_6$ - $C_{10}$  aryl, and  $C_7$ - $C_{10}$  aralkyl

ligands; is a non-coordinating anion; and

wherein two or three of L2, L3 and R are optionally connected.

This invention also provides novel compounds, I and II, which are useful in the process of this invention,



where

L<sup>4</sup> is an anionic pentahapto ligand;

I<sup>5</sup> is a neutral 2-electron donor ligand;

R<sup>11</sup> is selected from the group of  $C_1$ - $C_{10}$  alkyl; [X<sup>1</sup>]<sup>-</sup> is a non-coordinating anion; L<sup>6</sup> is an anionic pentahapto ligand; R<sup>12</sup> and R<sup>13</sup> are independently selected from the group consisting of  $C_1$ - $C_{10}$  alkyl; and

[X<sup>2</sup>] is a non-coordinating anion.

5

30

#### **DETAILED DESCRIPTION OF THE INVENTION**

The process of this invention can be used to homodimerize or codimerize functionalized terminal olefins in a linear, tail-to-tail fashion, or to dimerize functionalized terminal olefins with terminal alkenes. The products of the process of this invention are linear, functionalized olefins in which a carbon-carbon bond has been formed between the methylene carbons of the olefin reactants. Specific examples of useful products include dialkyl hexenedioates, which are precursors to adipic acid.

In the process of this invention, a linear functionalized olefin is prepared by reacting a first terminal olefin, CH<sub>2</sub> = CR<sup>1</sup>R<sup>2</sup>, with a second terminal olefin, CH<sub>2</sub> = CR<sup>3</sup>R<sup>4</sup>, in the presence of a cationic rhodium compound, [L<sup>1</sup>RhL<sup>2</sup>L<sup>3</sup>R]<sup>+</sup>X<sup>-</sup>; wherein

R¹ is selected from the group consisting of H and C1-C10 alkyl; R<sup>2</sup> is selected from the group consisting of H, C1-C10 alkyl, phenyl, C7-C12 alkylsubstituted phenyl, - COOR5, -C(O)NR6R7, and -C(O)H; R<sup>3</sup> is selected from the group consisting of H and C1-C10 alkyl; 20 R<sup>4</sup> is selected from the group consisting of - COOR8, -C(O)NR9R10, and -C(O)H; are independently selected from the group consisting of C1-C10 alkyl; R5 and R8 R6, R7, R9, and R10 are independently selected from the group consisting of H and C<sub>1</sub>-C<sub>10</sub> alkyl; L1 is an anionic pentahapto ligand;  $L^2$ 25 and L3 are neutral 2-electron donor ligands; R is selected from the group of H, C1-C10 alkyl, C6-C10 aryl, and C7-C10 aralkyl ligands;

X<sup>-</sup> is a non-coordinating anion; and wherein two or three of L<sup>2</sup>, L<sup>3</sup> and R are optionally connected.

Suitable terminal olefins,  $H_2C = CR^1R^2$ , include: ethylene; terminal alkenes containing 3-12 carbon atoms, e.g., propene, 1-butene, isoprene, 1-pentene, 1-hexene, and 1-heptene; styrene; 4-methylstyrene; alkyl acrylates, where the alkyl group contains 1-10 carbon atoms, e.g., methyl acrylate and ethyl acrylate; methyl methacrylate; acrylamide; methacrylamide; N-alkyl acrylamides, where the alkyl group contains 1-10 carbon atoms, e.g., N-methylacrylamide; N-methyl methacrylamide; N,N-dialkyl acrylamides, where the alkyl groups contain 1-10 carbon atoms, e.g., N,N-dimethylacrylamide; acrolein; and methacrolein.

Suitable functionalized terminal olefins,  $H_2C = CR^3R^4$ , include: alkyl acrylates, where the alkyl group contains 1-10 carbon atoms, e.g., methyl acrylate and ethyl acrylate; methyl methacrylate; acrylamide; methacrylamide; N-alkyl acrylamides, where the alkyl group contains 1-10 carbon atoms, e.g., N-methylacrylamide; N-methyl methacrylamide; N,N-dialkyl acrylamides, where the alkyl groups contain 1-10 carbon atoms, e.g., N,N-dimethylacrylamide; acrolein; and methacrolein.

Preferably,  $H_2C = CR^1R^2$  is ethylene, propylene, styrene, methyl acrylate, ethyl acrylate, acrolein, or N,N-dimethyl acrylamide. Preferably,  $H_2C = CR^3R^4$  is methyl acrylate, ethyl acrylate, acrolein, or N,N-dimethyl acrylamide. More preferably,  $H_2C = CR^1R^2$  is ethylene, styrene, methyl acrylate or ethyl acrylate and  $H_2C = CR^3R^4$  is methyl acrylate or ethyl acrylate. Most preferably,  $H_2C = CR^1R^2$  and  $H_2C = CR^3R^4$  are both either methyl acrylate or ethyl acrylate.

The terminal olefins,  $H_2C = CR^1R^2$  and  $H_2C = CR^3R^4$ , can be chosen to be the same or different olefins to give, respectively, homodimers or codimers. The efficiency of the production of codimers may depend on the specific olefins chosen, and thus it may be necessary to use a large excess of one of the olefins to obtain the desired codimer.

The cationic rhodium compound used in the process of this invention can be formed in one of several ways. A particularly convenient route involves reacting a precursor, L¹RhL²'L³', with an acid, H<sup>+</sup>X⁻, where

L<sup>1</sup> is an anionic pentahapto ligand;

L<sup>2</sup>' and L<sup>3</sup>' are neutral, 2-electron donor ligands, or L<sup>2</sup>' and L<sup>3</sup>' are connected to form a neutral, 4-electron ligand; and

55 X<sup>-</sup> is a non-coordinating anion.

For example, Cp\*Rh(C2H4)2 reacts with HBF4 to give

which is useful in the process of this invention. (Cp\* is pentamethylcyclopentadienyl.) Similarly, compound la (L4 is Cp\*; L5 is P(OMe)3; R11 is Me; and [X1] is BF4 can be made by reacting HBF4 with Cp\*Rh(P-(OMe)3)(CH2 = CHCO2Me). In these routes to cationic rhodium compounds, suitable acids, H<sup>\*</sup> X<sup>-</sup>, include: HBF4; HPF6; H<sub>2</sub>SO<sub>4</sub>; CF<sub>3</sub>SO<sub>3</sub>H; CF<sub>3</sub>CO<sub>2</sub>H; and tetraarylboronic acids, e.g., HBPh4 and HB(3,5-bis-(trifluoromethyl)phenyl)4.

Alternatively, L¹RhL²'(R)Y, where Y is a halide and L¹, L²', and R are as defined above, can be reacted with a Lewis acid in the presence of an olefin to form a cationic rhodium compound which is useful in the process of this invention. For example, Cp\*Rh(P(OMe)₃)(Me)Br could be reacted with AgBF₄ in the presence of methyl acrylate to give the desired cationic rhodium compound, [Cp\*Rh(P(OMe)₃)(CH₂ = CHCO₂Me)(Me)]-of methyl acrylate to give the desired cationic rhodium compound, [Cp\*Rh(P(OMe)₃)(CH₂ = CHCO₂Me)(Me)]-of methyl acrylate to give the desired cationic rhodium compound, [Cp\*Rh(P(OMe)₃)(CH₂ = CHCO₂Me)(Me)]-of methyl acrylate to give the desired cationic rhodium compound, [Cp\*Rh(P(OMe)₃)(CH₂ = CHCO₂Me)(Me)]-of methyl acrylate to give the desired cationic rhodium compound, [Cp\*Rh(P(OMe)₃)(CH₂ = CHCO₂Me)(Me)]-of methyl acrylate to give the desired cationic rhodium compound, [Cp\*Rh(P(OMe)₃)(CH₂ = CHCO₂Me)(Me)]-of methyl acrylate to give the desired cationic rhodium compound, [Cp\*Rh(P(OMe)₃)(CH₂ = CHCO₂Me)(Me)]-of methyl acrylate to give the desired cationic rhodium compound, [Cp\*Rh(P(OMe)₃)(CH₂ = CHCO₂Me)(Me)]-of methyl acrylate to give the desired cationic rhodium compound, [Cp\*Rh(P(OMe)₃)(CH₂ = CHCO₂Me)(Me)]-of methyl acrylate to give the desired cationic rhodium compound, [Cp\*Rh(P(OMe)₃)(CH₂ = CHCO₂Me)(Me)]-of methyl acrylate to give the desired cationic rhodium compound, [Cp\*Rh(P(OMe)₃)(CH₂ = CHCO₂Me)(Me)]-of methyl acrylate to give the desired cationic rhodium compound, [Cp\*Rh(P(OMe)₃)(CH₂ = CHCO₂Me)(Me)]-of methyl acrylate to give the desired cationic rhodium compound, [Cp\*Rh(P(OMe)₃)(CH₂ = CHCO₂Me)(Me)]-of methyl acrylate to give the desired cationic rhodium compound, [Cp\*Rh(P(OMe)₃)(CH₂ = CHCO₂Me)(Me)]-of methyl acrylate to give the desired cationic rhodium compound, [Cp\*Rh(P(OMe)₃)(CH₂ = CHCO₂Me)(Me)]-of methyl acrylate to give the desired cationic rhodium compound, [Cp\*Rh(P(OMe)₃)(CH₂ = CHCO₂Me)(Me)]-of methyl acrylate to give the desired cationic rhodium compound, [Cp\*Rh(P(OMe)₃)(CH₂ = CHCO₂Me)(Me

SbX''<sub>5</sub>, where X'' is halide.

In a third general route, precursors such as [L¹RhL²'L⁴]<sup>\*</sup>, where L⁴ is a π-allylic ligand and L¹ and L²'

In a third general route, precursors such as [L¹RhL²'L⁴]<sup>\*</sup>, where L⁴ is a π-allylic ligand and L¹ and L²'

are as defined above, can be reacted with H₂ to give cationic rhodium compounds which are useful in the process of this invention. For example, compounds of the class [Cp\*Rh(MeOC(O)CH₂CHCHCHCO₂Me)]<sup>\*</sup>X⁻

III,

In all of these rhodium compounds, suitable pentahapto ligands,  $L^1$ ,  $L^4$  and  $L^6$  include: cyclopentadienyl and substituted derivatives of cyclopentadienyl containing 1-5 substitutents chosen from  $C_1$ - $C_4$  alkyl, trifluoromethyl,  $C_6$ - $C_{10}$  aryl,  $COOR^{14}$  (where  $R^{14}$   $C_1$ - $C_4$  alkyl), and  $C(O)R^{15}$  (where  $R^{15}$  is  $C_1$ - $C_4$  alkyl); indenyl; fluorenyl; and carboranyl ligands such as (7,8,9,10,11- $\eta$ )undecahydro-7,8-dicarbaundecaborato(2-) and (7,8,9,10,11- $\eta$ )undecahydro-7,9-dicarbaundecaborato(2-). Preferably,  $L^1$ ,  $L^4$  and  $L^6$  are alkyl-substituted derivatives of cyclopentadienyl; most preferably,  $L^1$ ,  $L^4$  and  $L^6$  are pentamethylcyclopentadienyl ( $Cp^*$ ).

Suitable neutral, 2-electron donors, L², L³, L²', L³', and L⁵ include: carbon monoxide; alkyl-, aryl-, or mixed alkyl,arylphosphines (e.g., trimethylphosphine, triphenylphosphine, or diethylphenylphosphine); alkyl-, aryl-, or mixed alkyl,arylphosphites (e.g., trimethylphosphite, triphenylphosphite, or dimethylphenylphosphite); olefins (e.g., ethylene, propylene, 1-hexene, 1-octene, methyl acrylate, ethyl acrylate, or dimethyl hexenedioate); nitriles (e.g., acetonitrile or benzonitrile); and the carbonyl groups of ketones (e.g., acetone) and esters (e.g., methyl acrylate). L² and L³ can be the same or different, provided that if L² is a phosphine or phosphite, then L³ is not a phosphine or phosphite. Similarly, L²' and L³ can be the same or different, but cannot both be phosphine or phosphite ligands. Preferred 2-electron donors include carbon monoxide, ethylene, trimethylphosphite, methylacrylate and dimethyl hexenedioate.

Alternatively, L<sup>2</sup> and L<sup>3</sup>, or L<sup>2</sup> and L<sup>3</sup>, may be connected to form a neutral 4-electron donor ligand which contains two 2-electron-donor sites (olefin, phosphine, phosphite, nitrile or carbonyl groups). Suitable 4-electron-donor ligands of this type include: butadiene, 1,5-pentadiene, methyl vinyl ketone and acrylonitrile. Similarly, R and L<sup>2</sup> (or L<sup>2</sup>) can be connected, as in

Other suitable connected ligand systems include those in which L<sup>2</sup> and L<sup>4</sup> are connected (as in compound III), and those in which R is connected to L<sup>2</sup> and L<sup>3</sup> (as in [Cp\*Rh{CH(CH<sub>2</sub>CH<sub>2</sub>C(O)OMe)(CH<sub>2</sub>C(O)OMe)}]-X<sup>-</sup> (IIa), where L<sup>6</sup> is Cp\*, and R<sup>12</sup> and R<sup>13</sup> are Me).

Suitable R groups include: H;  $C_1$ - $C_{10}$  alkyl (e.g., methyl, ethyl, propyl, isoproyl, and butyl);  $C_6$ - $C_{10}$  aryl (e.g., phenyl, p-tolyl, and 3,5-dimethylphenyl); and  $C_7$ - $C_{10}$  aralkyl (e.g., benzyl, and -CH<sub>2</sub>CH<sub>2</sub>Ph).

[X]<sup>-</sup>, [X<sup>1</sup>]<sup>-</sup>, and [X<sup>2</sup>]<sup>-</sup> are anions which do not coordinate to the cationic rhodium compounds, and include BF<sub>4</sub><sup>-</sup>, PF<sub>6</sub><sup>-</sup>, CF<sub>3</sub>SO<sub>3</sub><sup>-</sup>, and tetraaryl borates such as [B{3,5-bis(trifluoromethyl)phenyl}<sub>4</sub>]<sup>-</sup> and BPh<sub>4</sub><sup>-</sup>.

The novel compounds, I and II,

$$\begin{bmatrix} L^4 \\ Rh \\ O \\ OR^{11} \end{bmatrix} + \begin{bmatrix} X^1 \end{bmatrix} \quad \text{and} \quad \begin{bmatrix} R^{12} \\ O \\ O \\ OR^{13} \end{bmatrix} + \begin{bmatrix} X^2 \end{bmatrix}$$

where

30

35

40

45

50

10

L<sup>4</sup> is an anionic pentahapto ligand;

L<sup>5</sup> is a neutral 2-electron donor ligand;

R<sup>11</sup> is selected from the group of C<sub>1</sub>-C<sub>10</sub> alkyl;

[X¹] is a non-coordinating anion; L<sup>6</sup> is an anionic pentahapto ligand;

R<sup>12</sup> and R<sup>13</sup> are independently selected from the group consisting of C<sub>1</sub>-C<sub>10</sub> alkyl; and

[X<sup>2</sup>] is a non-coordinating anion

are among the preferred cationic rhodium compounds for use in this invention. Preferably  $R^{11}$ ,  $R^{12}$  and  $R^{13}$  are methyl or ethyl, and [ $X^2$ ]<sup>-</sup> is a non-coordinating anion such as  $BF_4$ <sup>-</sup>,  $PF_6$ <sup>-</sup>,  $CF_3SO_3$ <sup>-</sup>,  $BPh_4$ <sup>-</sup>, or [B{3,5-bis(trifluoromethyl)phenyl}<sub>4</sub>]<sup>-</sup> are most preferred. Most preferably,  $L^5$  is CO or trimethylphosphite.

Other preferred cationic rhodium compounds include:

and  $[Cp^*Rh(P(OMe)_3)(CH_2 = CHCO_2Me)(Me)]^*X^-$ , where  $X^-$  is a non-coordinating anion such as  $BF_4^-$ ,  $PF_6^-$ ,  $CF_3SO_3^-$ ,  $BPh_4^-$ , or  $[B\{3,5-bis(trifluoromethyl)-phenyl\}_4]^-$ .  $BF_4^-$  and  $[B\{3,5-bis(trifluoromethyl)-phenyl]_4]^-$  are most preferred.

The cationic rhodium compound can be prepared *in situ* in the presence of the olefin(s) to be dimerized, or it can be prepared separately and then added to the olefin(s).

The amount of cationic rhodium compound used is not critical. Molar ratios of olefin/Rh of 2/1 to 10,000/1 have been demonstrated, and higher ratios are possible.

Suitable solvents for the process of this invention are those in which the catalyst and olefin(s) are at least partially soluble, and which are not reactive under the process conditions. Suitable solvents include halocarbons, ethers, esters, and aromatic solvents. Preferred solvents include dichloromethane and diethyl ether. Alternatively, this process may be run in the absence of solvent, depending on the olefin(s). For example, the dimerization of methyl acrylate can easily be carried out in neat acrylate.

Suitable temperatures for the process of this invention range from about -100°C to about 150°C,

depending on the specific catalyst, olefin(s) and pressure. More preferably, the temperature is between 0 ° C and 100°C; most preferably between 20°C and 80°C.

The process of this invention is not particularly sensitive to pressure, and pressures of 0.1 atm to 1,000 atm are suitable.

The process of this invention can be conducted in the presence of inert gases such as nitrogen, argon, helium, carbon dioxide and saturated hydrocarbons such as methane. In the preferred mode, the process is conducted in the presence of hydrogen, where the partial pressure of hydrogen is from about 0.1 atm to about 10 atm. Surprisingly, high yields of dimers are obtained and less than 3% saturated products are observed even under 1 atm hydrogen.

#### **EXAMPLES**

10

The following examples are provided to illustrate the invention and are not to be construed as limiting the invention. All preparative manipulations were carried out using conventional Schlenk techniques. Methylene chloride was distilled from P2O5 under a nitrogen atmosphere. Methyl acrylate was stored under 4Å molecular sieves. The rhodium complexes were prepared according to published procedures.

Reaction mixtures were analyzed by <sup>1</sup>H NMR spectroscopy. This method is advantageous since the fate of the rhodium species as well as the conversion of methyl acrylate into dimers can be monitored. The only dimers observed in all cases were linear, tail-to-tail dimers which included E- and Z-CH₃OC(0)-CH=CH- $CH_2-CH_2-CO_2CH_3$  (from here on referred to as E-2 and Z-2) and E-CH<sub>3</sub>OC(O)-CH<sub>2</sub>-CH=CH-CH<sub>2</sub>CO<sub>2</sub>CH<sub>3</sub> -(from here on referred to as E-3). Normally, the E-2 isomer was the major isomer. Small amounts of E-3 often appeared at the end of the reaction, probably due to isomerization of the E-2 and Z-2 isomers under the reaction conditions. The turnover number (TON) was defined as the number of moles of methyl acrylate consumed/mole of rhodium complex. The most efficient reactions were carried out under 1 atm H2. Under these conditions very little (<3%) hydrogenation of methylacrylate occurs.

Examples 1-3 demonstrate relatively inefficient dimerization employing Cp\*Rh(C2H4)(P(OMe)3) as starting material. In all these examples the reaction was followed by 1H NMR using NMR tubes sealed under vacuum.

#### Example 1 30

HBF<sub>4</sub>  $^{\bullet}$  Me<sub>2</sub>O (32  $\mu$ L, 0.287 mmol) is 5 mL diethyl ether was added at -30  $^{\circ}$  C to Cp\*Rh(C<sub>2</sub>H<sub>4</sub>)(P(OMe)<sub>3</sub>) (84 mg, 0.215 mmol) in 25 mL ether. The rhodium hydride salt [Cp\*Rh(C₂H₄)(P(OMe)₃)H]\*[BF₄]⁻ precipitated immediately. The mixture was cooled to -80°C and the ether solution was removed via cannula. The solid was washed with 2 portions of 5 mL of cold diethyl ether and dried under vacuum at low temperature.

Methyl acrylate (7.2 μL, 0.08 mmol) was added to an NMR tube at liquid nitrogen temperature containing  $[Cp^*Rh(C_2H_4)(P(OMe)_3)H]^*[BF_4]^-$  (8 mg, 0.017 mmol) in 0.6 mL  $CD_2Cl_2$ . The NMR tube was then sealed under vacuum. The reaction was monitored by <sup>1</sup>H NMR. A new complex Cp\*Rh-(CH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>Me)(P(OMe)<sub>3</sub>) was obtained and slow dimerization of the methyl acrylate was observed. (50% conversion after 9 days)

# Example 2

The new complex [Cp\*Rh(CH2CH2CO2Me)(P(OMe)3)] BF4 (la) was prepared starting from [Cp\*Rh- $(C_2H_4)(P(OMe)_3)H]^{\dagger}[BF_4]^{-}$  (140 mg, 0.293 mmol) and methyl acrylate (36  $\mu$ L, 0.40 mmol) in 5 mL  $CH_2Cl_2$ . Then methyl acrylate (250 µL, 2.78 mmol) was added at room temperature. Slow dimerization was obtained: 17% conversion after 24 h and 58% after 12 days.

NMR data for [Cp\*Rh(CH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>Me)(P(OMe)<sub>3</sub>)]\*BF<sub>4</sub> (la): ¹H NMR (CD<sub>2</sub>Cl<sub>2</sub>, 400 MHz, 23°C): δ3.79 (s,  $CO_2CH_3$ ), 3.71 (d,  $J_{P-H}=12$  Hz,  $P(OCH_3)_3$ ), 2.9 (m,  $CH_2$ ), 2.2 (m,  $CH_2$ ), 1.67 (d,  $J_{P-H}=4$  Hz,  $C_5(CH_3)_5$ ).  $^{13}C\{^{1}H\}$  NMR (CD<sub>2</sub>Cl<sub>2</sub>, 100 MHz, 23 °C):  $\delta$ 191.0 (s,  $CO_{2}CH_{3}$ ), 101.2 (s,  $C_{5}(CH_{3})_{5}$ ), 55.6 (s,  $CO_{2}CH_{3}$ ), 53.2 (d,  $J_{P-C} = 4$  Hz,  $P(OCH_3)_3$ ), 39.1 (s,  $CH_2CO_2CH_3$ ), 13.0 (t,  $J_{Rh-C} = J_{P-C} = 18$  Hz,  $RhCH_2$ ), 9.3 (s,  $\overline{C_5}(CH_3)_5$ ).

#### Example 3

Methyl acrylate (77  $\mu$ L, 0.86 mmol) was added to  $[Cp^*Rh(C_2H_4)(P(OMe)_3)H]^*[BF_4]^-$  (12 mg, 0.025) mmol) prepared following the method described in Example 1. After 4 days, 50% conversion to dimers was

Examples 4-13 demonstrate very efficient dimerization employing Cp\*Rh(C2H4)2 as starting material.

Only linear dimers were obtained.

#### Example 4

5

10

20

25

35

40

45

50

55

HBF<sub>4</sub> \*OMe<sub>2</sub> (one drop) was added at -40 \* C to Cp\*Rh( $C_2H_4$ )<sub>2</sub> (6 mg, 0.02 mmol) in 0.5 mL of CD<sub>2</sub>Cl<sub>2</sub> in an NMR tube. After shaking, the tube was frozen at liquid nitrogen temperature. Methyl acrylate (250  $\mu$ L, 2.78 mmol) was added and then the tube was sealed under vacuum at liquid nitrogen temperature. The reaction was then followed by NMR analysis at room temperature. After 45 min, 97% conversion to dimers was obtained. Dimers: E-2, 94%; Z-2, 4%; E-3, 2%.

#### Example 5

HBF<sub>4</sub>  $^{\circ}$  OMe<sub>2</sub> (one drop) was added at -50  $^{\circ}$  C to Cp\*Rh(C<sub>2</sub>H<sub>4</sub>)<sub>2</sub> (6 mg, 0.02 mmol) in 5 mL of CH<sub>2</sub>Cl<sub>2</sub> in a 100 mL Schlenk flask. Methyl acrylate (2.5 mL, 27.8 mmol) (degassed under N<sub>2</sub>) was added at -50  $^{\circ}$  C. The mixture was then stirred at 0  $^{\circ}$  C. The reaction was followed by NMR by withdrawing 50  $\mu$ L of the mixture and adding it to 0.5 mL of CD<sub>2</sub>Cl<sub>2</sub>. After 20 h at 0  $^{\circ}$  C, 63% conversion to dimers was obtained. Dimers: E-2, 86%; Z-2, 14%. TON = 876.

#### Example 6

The procedure described in Example 5 was repeated, except that the mixture was kept in a water bath at room temperature. After 3.83 h, 67% conversion to dimers was obtained. Dimers: E-2, 85%; Z-2, 18%. TON = 931.

In Examples 7-11 and 13, HBPh4 "indicates HB[3,5-bis(trifluoromethyl)phenyl]4.

#### Example 7

HBPh<sub>4</sub>\*\*\* (Et<sub>2</sub>O)<sub>2</sub> (29 mg, 0.029 mmol) was added to Cp\*Rh(C<sub>2</sub>H<sub>4</sub>)<sub>2</sub> (6 mg, 0.020 mmol) in 5 mL CH<sub>2</sub>Cl<sub>2</sub> at 0 ° C. Methyl acrylate (3 mL, 33.3 mmol) was added at 0 ° C and after 5 min the Schlenk flask was kept at room temperature in a water bath. Results are presented in the following table.

| Time (h) | %Conversion to dimers |  |  |
|----------|-----------------------|--|--|
| 0.25     | 5                     |  |  |
| 1 1      | 16                    |  |  |
| 3        | 45                    |  |  |
| 6        | 62                    |  |  |
| 24       | 75                    |  |  |

At 24 h, dimers were: E-2, 89%; Z-2, 11%. TON = 1249.

### Example 8

This example shows that the presence of a solvent is not necessary.

HBPh<sub>4</sub><sup>mo</sup> (Et<sub>2</sub>O)<sub>2</sub> (49 mg, 0.048 mmol) in 2 mL of diethyl ether was added at  $0^{\circ}$ C to Cp\*Rh(C<sub>2</sub>H<sub>4</sub>)<sub>2</sub> (10 mg, 0.034 mmol) in 2 mL of diethyl ether. After stirring 7 min, the mixture was evaporated to dryness at  $0^{\circ}$ C under vacuum. Then methyl acrylate (8 mL, 88.9 mmol) was added at  $0^{\circ}$ C to the remaining solid. After stirring 5 min, the Schlenk flask was kept in a water bath at room temperature. 47% conversion was obtained: E-2, 88%; Z-2, 12%. TON = 1229.

#### Example 9

This example shows that dimerization occurs at a temperature as low as -80 °C.

HBPh<sub>4</sub><sup>m</sup>\* (Et<sub>2</sub>O)<sub>2</sub> (38 mg, 0.037 mmol) in 0.3 mL CD<sub>2</sub>Cl<sub>2</sub> was added at 0 °C to Cp\*Rh(C<sub>2</sub>H<sub>4</sub>)<sub>2</sub> (7 mg, 0.024 mmol) in 0.5 mL CD<sub>2</sub>Cl<sub>2</sub> in an NMR tube. After cooling to -80 °C, methyl acrylate (20  $\mu$ L, 0.222 mmol) was added, and the tube was shaken just before its introduction into the NMR probe. Dimerization was observed at -80 °C, but the reaction was very slow.

In Examples 10-13, the reactions were performed using  $N_2$  and  $H_2$  atmospheres.

#### Example 10

HBPh<sub>4</sub><sup>\*\*\*</sup> (Et<sub>2</sub>O)<sub>2</sub> (49 mg, 0.048 mmol) in 2 mL CH<sub>2</sub>Cl<sub>2</sub> was added at 0 °C to Cp\*Rh(C<sub>2</sub>H<sub>4</sub>)<sub>2</sub> (10 mg, 0.034 mmol) in 10 mL CH<sub>2</sub>Cl<sub>2</sub>. After stirring 10 min, methyl acrylate (8 mL, 88.9 mmol) was added to the mixture. The Schlenk flask was then kept at room temperature in a water bath. After 4 h reaction under N<sub>2</sub> atmosphere, 36% conversion to dimers was obtained. At this point, the mixture was divided into two fractions: one fraction was kept under N<sub>2</sub> and 47% conversion was finally obtained. H<sub>2</sub> was bubbled through the second fraction for 1 h, and 95% conversion to dimers was finally obtained. TON = 2483 (H<sub>2</sub> atmosphere).

# Example 11

 $HBPh_4^{\text{ere}}$  (Et<sub>2</sub>O)<sub>2</sub> (50 mg, 0.049 mmol) in 1.5 mL  $CH_2Cl_2$  was added at 0°C to  $Cp^*Rh(C_2H_4)_2$  (10 mg, 0.034 mmol) in 2.5 mL  $CH_2Cl_2$ . After stirring 10 min, methyl acrylate (20 mL, 222.3 mmol) was added to the solution. The Schlenk flask was then kept at room temperature in a water bath under  $H_2$  atmosphere. The results are reported in the following table:

| %Conversion to dimers |  |  |
|-----------------------|--|--|
| 14                    |  |  |
| <b>6</b> 8            |  |  |
| >99.9                 |  |  |
| ֡                     |  |  |

25

15

20

At 48 h, TON = 6538.

Turnover rate = 3.5 mol CH<sub>2</sub> = CHCO<sub>2</sub> Me/mol(Rh)/min at 25 ° C.

Dimers: E-2, 95%; Z-2, 3%; E-3, 2%.

# 30 Example 12

One drop of HBF4  $^{\circ}$  Me<sub>2</sub>O was added at -40  $^{\circ}$ C to Cp $^{\circ}$ Rh(C<sub>2</sub>H<sub>4</sub>)<sub>2</sub> (10 mg, 0.034 mmol) in 10 mL of CH<sub>2</sub>Cl<sub>2</sub>. Methyl acrylate (8 mL, 88.9 mmol) was added to the mixture, and the mixture was then heated to 40-50  $^{\circ}$ C under an H<sub>2</sub> atmosphere. (The Schlenk flask was equipped with a water condenser.) The reaction was only monitored for 4 h and at that point, 69% conversion was obtained.

Turnover rate = 7.5 mol CH<sub>2</sub> = CHCO<sub>2</sub> Me/mol(Rh)/min at 40 ° C.

#### Example 13

HBPh<sub>4</sub> <sup>see</sup> (Et<sub>2</sub>O)<sub>2</sub> (50 mg, 0.049 mmol) in 3 mL CH<sub>2</sub>Cl<sub>2</sub> was added at 0°C to Cp\*Rh(C<sub>2</sub>H<sub>4</sub>)<sub>2</sub> (10 mg, 0.034 mmol) in 3 mL CH<sub>2</sub>Cl<sub>2</sub>. After stirring 10 min, methyl acrylate (20 mL, 222.3 mmol) was added to the solution. The Schlenk flask was then kept at room temperature in a water bath under H<sub>2</sub> atmosphere. The results are reported in the following table:

45

40

50

| Time (h) | %Conversion to dimers |  |  |
|----------|-----------------------|--|--|
| 2        | 12                    |  |  |
| 3.25     | 20                    |  |  |
| 4.33     | 27                    |  |  |
| 5.33     | 33                    |  |  |
| 7.75     | 47                    |  |  |
| 9.75     | 59                    |  |  |
| 11.50    | 67                    |  |  |
| 12.92    | 75                    |  |  |
| 14.83    | 84                    |  |  |
| 16.75    | 91                    |  |  |
| 18.50    | 95                    |  |  |
| 20.33    | 97                    |  |  |

After 11.50 h, the mixture was frozen in dry ice/acetone overnight. Just after thawing, no change was noticed in the monomer/dimer ratio and the reaction was then monitored in the same manner as before freezing. After 36 h at room temperature, >99.9% conversion was obtained, giving a TON = 6538. (No data points were taken between 20.33 and 36 h.)

Turnover rate =  $6.6 \text{ mol CH}_2 = \text{CHCO}_2\text{Me/mol(Rh)/min at } 25 \,^{\circ}\text{C}$  (over the initial 10 h period).

Dimers: E-2, 94%; Z-2, 5%; E-3, 1%.

#### Example 14

5

10

15

25

35

50

The procedure described in Example 13 was repeated, except that the mixture was heated to 60°C under H<sub>2</sub> atmosphere.

After 3 h, 94% conversion was obtained. An additional 20 mL of methyl acrylate was added, and after 22 h, 99% conversion was obtained at 60 °C, giving a TON = 13,000.

Turnover rate = 65 mol CH<sub>2</sub> = CHCO<sub>2</sub>Me/mol(Rh)/min at 60 ° C (over the initial (1 h ) period).

Products: Dimers (98%): E-2, 93%; Z-2, 6%; E-3, 1%

Methyl propionate (2%).

### Example 15

This example describes the synthesis (2 methods) and the characterization of the new complexes  $[Cp^*RhCH(CH_2CO_2Me)(CH_2CO_2Me)]^{\dagger}[BPh_4^*]^{-}$  (IIb) and  $\{Cp^*Rh(\eta^3-MeOC(O)CH_2CHCHCHCO_2Me)]^{\dagger}-[BPh_4^*]^{-}$  (IIIb).

Method 1: HBPh<sub>4</sub><sup>m\*\*</sup> (Et<sub>2</sub>O)<sub>2</sub> (218 mg, 0.215 mmol) in 3 mL CH<sub>2</sub>Cl<sub>2</sub> was added at 0 ° C to Cp\*Rh(C<sub>2</sub>H<sub>4</sub>)<sub>2</sub> (49 mg, 0.167 mmol) in 7 mL CH<sub>2</sub>Cl<sub>2</sub>. After stirring 10 min, MeOC(O)CH = CHCH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>Me (200  $\mu$ L) was added to the mixture. After stirring overnight at room temperature, the solution was evaporated to dryness. The residue was washed with hexane to eliminate the dimer. The two complexes (IIb) and (IIIb) were separated by successive recrystallizations in diethyl ether/hexane and isolated as orange crystals.

Method 2: HBPh<sub>4</sub><sup>m\*\*</sup> (Et<sub>2</sub>O)<sub>2</sub> (171 mg, 0.169 mmol) in 3 mL CH<sub>2</sub>Cl<sub>2</sub> was added at 0 ° C to Cp\*Rh(C<sub>2</sub>H<sub>4</sub>)<sub>2</sub> (39 mg, 0.133 mmol) in 7 mL CH<sub>2</sub>Cl<sub>2</sub>. After stirring 10 min, methyl acrylate (240 μL, 2.668 mmol) was added to the mixture. After stirring overnight at room temperature, the solution was evaporated to dryness. The residue was washed with hexane to eliminate excess dimer. The two complexes (IIb) and (IIIb) were separated by successive recrystallizations in diethyl ether/hexane and isolated as orange crystals. NMR data for [Cp\*RhCH(CH<sub>2</sub>CO<sub>2</sub>Me)(CH<sub>2</sub>CO<sub>2</sub>Me)]<sup>†</sup>[BPh<sub>4</sub><sup>m\*</sup>]<sup>-</sup>(IIb):

<sup>1</sup>H NMR (400 MHz, CD<sub>2</sub>Cl<sub>2</sub>, 23°C):  $\delta$ 7.72 (Ph<sup>m</sup>, 8H), 7.56 (Ph<sup>m</sup>, 4H), 3.93 (s, CO<sub>2</sub>CH<sub>3</sub>), 3.84 (s, CO<sub>2</sub>CH<sub>3</sub>), 3.35 (m, broad, Ha), 3.00 (dd, J<sub>Ha-Hb or c</sub> = 9 Hz, J<sub>Hb-Hc</sub> = 19 Hz, Hb or c), 2.68 (d, J<sub>Hb-Hc</sub>) = 19 Hz, Hc or b), 2.40 (ddd, J = 3, 7 and 19 Hz, Hf or g), 2.15 (ddd, J = 3, 9 and 19 Hz, Hg or f), 1.68 (m, Hd or e), 1.53 (s, C<sub>5</sub>(CH<sub>3</sub>)<sub>5</sub>), 1.52 (m, He or d).

<sup>13</sup>C NMR (100 MHz, CD<sub>2</sub>Cl<sub>2</sub>, 23 °C): δ190.4 (s, CO<sub>2</sub>CH<sub>3</sub>), 183.0 (s, CO<sub>2</sub>CH<sub>3</sub>), 162.1 (q, J<sub>C-B</sub> = 50 Hz, C1'), 135.2 (d, J<sub>C-H</sub> = 157.5 Hz, C2' and C6'), 129.3 (q,  $^2$ J<sub>C-F</sub> = 32 Hz,  $\overline{C3}$ ' and C5'), 125.0 (q, J<sub>C-F</sub> = 273 Hz, CF<sub>3</sub>) 117.9 (dq, J<sub>C-H</sub> = 163 Hz,  $^3$ J<sub>C-F</sub> = 4 Hz, C4'), 94.6 (d, J<sub>C-Rh</sub> = 8 Hz, C<sub>5</sub>(CH<sub>3</sub>)<sub>5</sub>), 55.7 (q, J<sub>C-H</sub> = 150 Hz, CO<sub>2</sub>CH<sub>3</sub>), 54.9 (q, J<sub>C-H</sub> = 150 Hz, CO<sub>2</sub>CH<sub>3</sub>), 44.8 (t, J<sub>C-H</sub> = 130 Hz, CH<sub>2</sub>), 38.7 (dd, J<sub>C-Rh</sub> = 23 Hz, J<sub>C-H</sub> = 140 Hz, Rh-CH), 31.6 (t, J<sub>C-H</sub> = 130 Hz, CH<sub>2</sub>), 29.9 (t, J<sub>C-H</sub> = 130, CH<sub>2</sub>), 8.9 (q, J<sub>C-H</sub> = 129 Hz, C<sub>5</sub>-

(CH<sub>3</sub>)<sub>5</sub>).

10

15

IIb

NMR data for [Cp\*Rh(η³-MeOC(O)CH<sub>2</sub>CHCHCHCO<sub>2</sub>Me)]<sup>\*</sup>[BPh<sub>4</sub>\*\*]<sup>-</sup>(IIIb):

<sup>1</sup>H NMR (400 MHz, CD<sub>2</sub>Cl<sub>2</sub>, 23 °C): δ7.72 (Ph\*\*, 8H), 7.56 (Ph\*\*, 4H), 5.49 (ddd,  $J_{Ha-Hb}$  = 11 Hz,  $J_{Hc-Hb}$  = 8 Hz,  $J_{Rh-Hb}$  = 2 Hz, Hb), 4.70 (ddd,  $J_{Hb-Hc}$  = 8 Hz,  $J_{Hc-Hd}$  = 7.5 Hz,  $J_{Hc-He}$  = 2 Hz, Hc), 3.85 (s, CO<sub>2</sub>CH<sub>3</sub>), 3.82 (s, CO<sub>2</sub>CH<sub>3</sub>), 3.42 (dd,  $J_{Hd-Hc}$  = 7.5 Hz,  $J_{Hd-He}$  = 21 Hz, Hd), 3.11 (d,  $J_{Ha-Hb}$  = 11 Hz, Ha), 2.61 (dd,  $J_{He-Hd}$  = 21 Hz,  $J_{He-Hc}$  = 2 Hz, He), 1.70 (s, C<sub>5</sub>(CH<sub>3</sub>)<sub>5</sub>).

<sup>13</sup>C{<sup>1</sup>H} NMR (100 MHz, CD<sub>2</sub>Cl<sub>2</sub>, 23 °C): δ186.8 (s, C5), 170.0 (s, C6), 162.1 (q, J<sub>C-B</sub> = 50 Hz, C1'), 135.2 (s, C2' and C6'), 129.3 (q,  $^2$ J<sub>C-F</sub> = 32 Hz, C3' and C5'), 125.0 (q, J<sub>C-F</sub> = 273 Hz, CF<sub>3</sub>), 117.9 (q,  $^3$ J<sub>C-F</sub> = 4 Hz, C4'), 102.5 (d, J<sub>C-Rh</sub> = 5 Hz, C2), 101.3 (d, J<sub>C-Rh</sub> = 7 Hz, C<sub>5</sub>(CH<sub>3</sub>)<sub>5</sub>), 71.6 (d, J<sub>C-Rh</sub> = 9 Hz, C3), 67.8 (d, J<sub>C-Rh</sub> = 10 Hz, C1), 56.5 (s, OCH<sub>3</sub>), 52.5 (s, OCH<sub>3</sub>), 36.5, (s, C4), 8.9 (s, C<sub>5</sub>(CH<sub>3</sub>)<sub>5</sub>).

 $^{13}\text{C}$  NMR (100 MHz,  $\text{CD}_2\text{Cl}_2$ ,  $23\,^{\circ}\overline{\text{C}}$ ):  $\delta186.8$  (s, C5), 170.0 (s, C6), 162.1 (q,  $\text{J}_{C.B}$  = 50 Hz, C1'), 135.2 (d,  $\text{J}_{C.H}$  = 157.5 Hz, C2' and C6'), 129.3 (q,  $^2\text{J}_{C.F}$  = 32 Hz, C3' and C5'), 125.0 (q,  $\text{J}_{C.F}$  = 273 Hz, CF<sub>3</sub>), 117.9 (dq,  $\text{J}_{C.H}$  = 163 Hz,  $^3\text{J}_{C.F}$  = 4 Hz, C4'), 102.5 (m,  $\text{J}_{C.H}$  = 170 Hz, C2), 101.3 (d,  $\text{J}_{C.Rh}$  = 7 Hz, C5-(CH<sub>3</sub>)<sub>5</sub>), 71.6 (m,  $\text{J}_{C.H}$  = 160 Hz, C3), 67.8 (dt,  $\text{J}_{C.H}$  = 161 Hz,  $^1\text{J}_{C.Rh}$  =  $^2\text{J}_{C.Hb}$  = 10 Hz, C1), 56.5 (q,  $\text{J}_{C.H}$  = 151 Hz, OCH<sub>3</sub>), 52.5 (q,  $\text{J}_{C.H}$  = 148 Hz, OCH<sub>3</sub>), 36.5, (t,  $\text{J}_{C.H}$  = 130 Hz, C4), 8.9 (q,  $\text{J}_{C.H}$  = 129 Hz, C5-(CH<sub>3</sub>)<sub>5</sub>).

$$\begin{array}{c} & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & & \\ & &$$

# Claims

50

55

1. A process for preparing functionalized linear olefins which comprises reacting a first olefin,  $H_2C = CR^1R^2$ , with a second olefin,  $H_2C = CR^3R^4$ , in the presence of a cationic rhodium compound,  $[L^1RhL^2L^3R]^{\dagger}X^{-}$ ; wherein

R¹ R² is selected from the group consisting of H and  $C_1$ - $C_{10}$  alkyl; is selected from the group consisting of H,  $C_1$ - $C_{10}$  alkyl, phenyl,  $C_7$ - $C_{12}$  alkyl-substituted phenyl, -COOR<sup>5</sup>, -C(O)NR<sup>6</sup>R<sup>7</sup>, and -C(O)H;

|    | $R^3$ $R^4$ $R^5$ and $R^8$ $R^6$ , $R^7$ , $R^9$ , and $R^{10}$ | is selected from the group consisting of H and $C_1$ - $C_{10}$ alkyl; is selected from the group consisting of - COOR <sup>8</sup> , -C(O)NR <sup>9</sup> R <sup>10</sup> , and -C(O)H; are independently selected from the group consisting of $C_1$ - $C_{10}$ alkyl; are independently selected from the group consisting of H and $C_1$ - $C_{10}$ alkyl; |
|----|--|--|
| 5  | L'   | is an anionic pentahapto ligand;   |
|    | L <sup>2</sup> and L <sup>3</sup>                                | are neutral 2-electron donor ligands;  |
|    | R  | is selected from the group of H, C <sub>1</sub> -C <sub>10</sub> alkyl, C <sub>6</sub> -C <sub>10</sub> aryl, and C <sub>7</sub> -C <sub>10</sub> aralkyl ligands;   |
|    | <b>x</b> -   | is a non-coordinating anion; and wherein two or three of L2, L3 and R are  |
| 10 |  | optionally connected.  |

- A process according to Claim 1 wherein said process is carried out between the temperatures of -100°C to 150°C.
- 3. A process according to Claim 2 wherein said first olefin is selected from the group consisting of ethylene, propylene, styrene, methyl acrylate, ethyl acrylate, acrolein, and N,N-dimethyl acrylate, acrolein, and said second olefin is selected from the group consisting of methyl acrylate, ethyl acrylate, acrolein, and N,N-dimethyl acrylamide.
- 20 4. A process according to Claim 3 wherein L<sup>1</sup> is pentamethylcyclopentadienyl.
  - 5. A process according to Claim 4 in which said first olefin is selected from the group consisting of ethylene, styrene, methyl acrylate and ethyl acrylate, and said second olefin is selected from the group consisting of methyl acrylate and ethyl acrylate.
  - **6.** A process according to Claim 5 in which said cationic rhodium compound is selected from the group consisting of:

 $[Cp^*Rh(P(OMe)_3)(CH_2 = CHCO_2Me)(Me)]^*BF_4^-;$   $[Cp^*Rh(CH_2CH_2C(O)OMe)(P(OMe)_3)]^*BF_4^-;$  $[Cp^*Rh\{CH(CH_2CH_2C(O)OMe)(CH_2C(O)OMe)\}]^*BF_4^-;$ 

[Cp\*Rh(CH2CH2..H)(C2H4)]+[BPh4\*\*]-;

- 7. A process according to Claim 6 in which the partial pressure of hydrogen is 0.1 to 10 atm.
- 8. A process according to Claim 7 in which said first olefin is methyl acrylate and said second olefin is methyl acrylate.
- 9. A compound of the formula

50

45

25

30

35

10

15

5

where

is an anionic pentahapto ligand; L<sup>4</sup>

is a neutral 2-electron donor ligand; L<sup>5</sup>

is selected from the group of C1-C10 alkyl; and R<sup>11</sup>

is a non-coordinating anion. [Y1]

- 10. A compound according to Claim 9 wherein L4 is pentamethylcyclopentadienyl, and L5 is chosen from the group consisting of CO and trimethylphosphite.
  - 11. A compound according to Claim 10 wherein L<sup>5</sup> is trimethylphosphite and R<sup>11</sup> is methyl.
- 12. A compound of the formula

30 35

40

where

is an anionic pentahapto ligand;

are independently selected from the group consisting of C1-C10 alkyl; and R12 and R13

is a non-coordinating anion.  $[X^2]$ 

13. A compound according to Claim 12 wherein L<sup>5</sup> is pentamethylcyclopentadienyl, and R<sup>12</sup> and R<sup>13</sup> are methyl.

50

45





11) Publication number:

0 475 386 A3

(12)

### **EUROPEAN PATENT APPLICATION**

21 Application number: 91115381.5

2 Date of filing: 11.09.91

(a) Int. Cl.5: **C07C 69/593**, C07C 67/347, C07C 45/72, C07C 231/12, C07F 15/00, C07F 17/00

(3) Priority: 11.09.90 US 580919

Date of publication of application:
 18.03.92 Bulletin 92/12

Designated Contracting States:
BE DE ES FR GB IT NL

Date of deferred publication of the search report: 12.05.93 Bulletin 93/19 7) Applicant: THE UNIVERSITY OF NORTH
CAROLINA AT CHAPEL HILL
Office of Research Services, CB 4100, 300
Bynum Hall
Chapel Hill, NC 27599-4100(US)

Inventor: Brookhart, Maurice S. Route 7, Box 648-B Chapel Hill, North Carolina 27514(US) Inventor: Sabo-Etienne Sylviane 13, rue Flora Tristan F-31320 Castanet Tolosan(FR)

Representative: Abitz, Walter, Dr.-Ing. et al Abitz, Morf, Gritschneder, Freiherr von Wittgenstein Postfach 86 01 09 W-8000 München 86 (DE)

- Rhodium catalyzed olefin dimerization.
- A process is disclosed for preparing functionalized linear olefins by dimerizing terminal olefins in the presence of a cationic rhodium compound. Novel rhodium compounds useful in this process are also disclosed.



# **EUROPEAN SEARCH REPORT**

Application Number

EP 91 11 5381 . 5

| :                           | DOCUMENTS CONSI  | DERED TO BE   | RELEVAN  | Γ  | ]   |
|-----------------------------|--|---|--|--|---|
| Category                    | Citation of document with it of relevant pa  |   | printe,  | Relevant<br>to claim   | CLASSIFICATION OF THE APPLICATION (Int. CL5)                                  |
| D,X                         | JOURNAL OF THE AMER vol. 110, 1988, WAS pages 8719 - 8720 BROOKHART ET AL 'C aptitudes of hydrid beta-migratory inse Cp*(P(OMe)3)Rh(C2H4 * the whole documen   | HINGTON D.C. omparison of a le and alkyl grant reaction: )R+1 | ,US<br>migratory<br>roups in   | 1-4  | C07C69/593<br>C07C67/347<br>C07C45/72<br>C07C231/12<br>C07F15/00<br>C07F17/00 |
| Ρ,Χ                         | JOURNAL OF THE AMER vol. 113, no. 7, 27 D.C. ,US pages 2777 - 2779 BROOKHART ET AL 'C dimerization of met Rh(III) catalysts' * the whole documen   | March 1991, Natalytic tail                                    | wASHINGTON<br>to tail  | 1-12   |   |
| A                           | JOURNAL OF THE AMERICAN CHEMICAL SOCIETY vol. 87, no. 24, 1965, WASHINGTON D.C., US pages 5638 - 5645 ALDERSON ET AL 'Olefin-to olefin addition reactions' * the whole document *                                  |   |  | 1-8  | TECHNICAL FIELDS SEARCHED (Int. Cl.5) CO7C                                    |
| D,A                         | US-A-4 638 084 (D M<br>* example *   | SINGLETON)  |  | 1-8  | C07F  |
| A                           | US-A-3 636 122 (R D<br>* claims *  | CRAMER ET AL  | )  | 1  |   |
|                             |  |   |  |  |   |
|                             | The present search report has  | been drawn up for all c                                       | lains  |  |   |
|                             | Place of search THE HAGUE  | Date of cample<br>17 MARCH                                    | lation of the counts   |  | HEYWOOD C.J.  |
| Y:pa<br>do<br>A:ter<br>O:no | CATEGORY OF CITED DOCUME<br>rticularly relevant if taken alone<br>rticularly relevant if combined with an<br>cument of the same category<br>chnological background<br>on-written disclosure<br>termediate document | nother  | T: theory or princip E: earlier patent to after the filing D: document cited L: document cited d: member of the s document | cament, but pu<br>late<br>in the applicati<br>for other reason | blished oo, or<br>on<br>s   |

EPO PORM 1503 03.42 (POM)